fesoterodine (toviaz) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fesoterodine (trade name Toviaz) is a prodrug of 5-hydroxymethyl tolterodine, which is also the active metabolite of tolterodine. Fesoterodine and its active metabolites are nonsubtype selective, competitive antagonists of human muscarinic receptors, but 5-hydroxymethyl tolterodine has greater potency than the parent compound. A prodrug approach was necessary for systemic bioavailability of 5-hydroxymethyl tolterodine after oral administration. Fesoterodine was originated by Schwarz Pharma (later a subsidiary of UCB) and is being developed by Pfizer for the treatment of overactive bladder and urinary urge incontinence. The agent is launched in several countries for the treatment of overactive bladder, including the US, Japan, Canada, Europe and Asia.   NCATS

Chemistry

  • SMILES: CC(C)N(CC[C@H](c1ccccc1)c2cc(CO)ccc2OC(=O)C(C)C)C(C)C
  • InChIKey: DCCSDBARQIPTGU-HSZRJFAPSA-N
  • Mol. Mass: 411.59
  • ALogP: 5.38
  • ChEMBL Molecules:
    fesoterodine  
    fesoterodine fumarate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$8.2033 - $11.4670
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

fes | feso | fesoterodine | fesoterodine fumarate | spm-8272 | spm-907 | toviaz

Organizations (51)

Research & Development (35)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Urinary Bladder, Overactive

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Autonomic Dysreflexia (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Intraductal, Noninfiltrating (Phase 2)

Cognitive Dysfunction (Phase 2)

Food (Phase 1)

Healthy Volunteers (Phase 1)

Nocturia (Phase 2/Phase 3)

Parkinson Disease (Phase 4)

Prostatic Neoplasms (Phase 4)

Therapeutic Equivalency (Phase 1)

Urinary Bladder (Phase 2)

Urinary Bladder Neck Obstruction (Phase 4)

Urinary Bladder, Neurogenic (Phase 3)

Urinary Bladder, Overactive ()

Urinary Incontinence, Stress (Phase 2)

Urinary Incontinence, Urge (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial Organizations: 35

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue